Klarer AC - Search Results

1

Klarer AC, McGregor W. Klarer AC, et al. Crit Rev Eukaryot Gene Expr. 2011;21(4):323-36. doi: 10.1615/critreveukargeneexpr.v21.i4.30. Crit Rev Eukaryot Gene Expr. 2011. PMID: 22181702 Review.

2

DNA polymerase eta participates in the mutagenic bypass of adducts induced by benzo[a]pyrene diol epoxide in mammalian cells.

Klarer AC, Stallons LJ, Burke TJ, Skaggs RL, McGregor WG. Klarer AC, et al. PLoS One. 2012;7(6):e39596. doi: 10.1371/journal.pone.0039596. Epub 2012 Jun 20. PLoS One. 2012. PMID: 22745795 Free PMC article.

3

Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma.

Telang S, Rasku MA, Clem AL, Carter K, Klarer AC, Badger WR, Milam RA, Rai SN, Pan J, Gragg H, Clem BF, McMasters KM, Miller DM, Chesney J. Telang S, et al. Among authors: klarer ac. BMC Cancer. 2011 Dec 13;11:515. doi: 10.1186/1471-2407-11-515. BMC Cancer. 2011. PMID: 22165955 Free PMC article. Clinical Trial.

4

Small molecule inhibition of 6-phosphofructo-2-kinase suppresses t cell activation.

Telang S, Clem BF, Klarer AC, Clem AL, Trent JO, Bucala R, Chesney J. Telang S, et al. Among authors: klarer ac. J Transl Med. 2012 May 16;10:95. doi: 10.1186/1479-5876-10-95. J Transl Med. 2012. PMID: 22591674 Free PMC article.

5

Fructose-2,6-bisphosphate synthesis by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4) is required for the glycolytic response to hypoxia and tumor growth.

Chesney J, Clark J, Klarer AC, Imbert-Fernandez Y, Lane AN, Telang S. Chesney J, et al. Among authors: klarer ac. Oncotarget. 2014 Aug 30;5(16):6670-86. doi: 10.18632/oncotarget.2213. Oncotarget. 2014. PMID: 25115398 Free PMC article.

6

Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer.

Clem BF, O'Neal J, Tapolsky G, Clem AL, Imbert-Fernandez Y, Kerr DA 2nd, Klarer AC, Redman R, Miller DM, Trent JO, Telang S, Chesney J. Clem BF, et al. Among authors: klarer ac. Mol Cancer Ther. 2013 Aug;12(8):1461-70. doi: 10.1158/1535-7163.MCT-13-0097. Epub 2013 May 14. Mol Cancer Ther. 2013. PMID: 23674815 Free PMC article.

7

Inhibition of 6-phosphofructo-2-kinase (PFKFB3) induces autophagy as a survival mechanism.

Klarer AC, O'Neal J, Imbert-Fernandez Y, Clem A, Ellis SR, Clark J, Clem B, Chesney J, Telang S. Klarer AC, et al. Cancer Metab. 2014 Jan 23;2(1):2. doi: 10.1186/2049-3002-2-2. Cancer Metab. 2014. PMID: 24451478 Free PMC article.

8

Cytochrome c oxidase is activated by the oncoprotein Ras and is required for A549 lung adenocarcinoma growth.

Telang S, Nelson KK, Siow DL, Yalcin A, Thornburg JM, Imbert-Fernandez Y, Klarer AC, Farghaly H, Clem BF, Eaton JW, Chesney J. Telang S, et al. Among authors: klarer ac. Mol Cancer. 2012 Aug 23;11:60. doi: 10.1186/1476-4598-11-60. Mol Cancer. 2012. PMID: 22917272 Free PMC article.

9

6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27.

Yalcin A, Clem BF, Imbert-Fernandez Y, Ozcan SC, Peker S, O'Neal J, Klarer AC, Clem AL, Telang S, Chesney J. Yalcin A, et al. Among authors: klarer ac. Cell Death Dis. 2014 Jul 17;5(7):e1337. doi: 10.1038/cddis.2014.292. Cell Death Dis. 2014. PMID: 25032860 Free PMC article.

10

Clinical development of cancer therapeutics that target metabolism.

Clem BF, O'Neal J, Klarer AC, Telang S, Chesney J. Clem BF, et al. Among authors: klarer ac. QJM. 2016 Jun;109(6):367-72. doi: 10.1093/qjmed/hcv181. Epub 2015 Oct 1. QJM. 2016. PMID: 26428335 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

10 results

Search Page

Filters